BR0101294A - Métodos de triagem de um composto que modula a atividade do canal de cálcio, e para bloqueadores e para estimuladores de icrac, kit para uso em um método, célula sanguìnea ou célula derivada do sangue, linfócito ou célula derivada de linfócito, ou mastócito ou célula derivada de mastócito, e, população de células imunes de roedores - Google Patents

Métodos de triagem de um composto que modula a atividade do canal de cálcio, e para bloqueadores e para estimuladores de icrac, kit para uso em um método, célula sanguìnea ou célula derivada do sangue, linfócito ou célula derivada de linfócito, ou mastócito ou célula derivada de mastócito, e, população de células imunes de roedores

Info

Publication number
BR0101294A
BR0101294A BR0101294-0A BR0101294A BR0101294A BR 0101294 A BR0101294 A BR 0101294A BR 0101294 A BR0101294 A BR 0101294A BR 0101294 A BR0101294 A BR 0101294A
Authority
BR
Brazil
Prior art keywords
cell
cells
derived
blood
lymphocyte
Prior art date
Application number
BR0101294-0A
Other languages
English (en)
Inventor
Emmanuel Normant
Janet Allen
Francois Roman
Gilles Brunelle
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0101294A publication Critical patent/BR0101294A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"MéTODOS DE TRIAGEM DE UM COMPOSTO QUE MODULA A ATIVIDADE DO CANAL DE CáLCIO, E PARA BLOQUEADORES E PARA ESTIMULADORES DE ICRAC, KIT PARA USO EM UM MéTODO, CéLULA SANGuìNEA OU CéLULA DERIVADA DO SANGUE, LINFóCITO OU CéLULA DERIVADA DE LINFóCITO, OU MASTóCITO OU CéLULA DERIVADA DE MASTóCITO, POPULAçãO DE CéLULAS IMUNES DE ROEDORES". A presente invenção diz respeito a composições e métodos direcionados à triagem ou caracterização de compostos que modulam a atividade de canais de cálcio em células, preferivelmente canais ativados por liberação de cálcio nas células. As composições e métodos podem ser usados para produzir inibidores ou ativadores do dito canal, que representa condutores ou medicamentos terapêuticos candidatos para tratar várias condições patológicas. Mais especificamente, o método compreende (a) colocar em contato um composto de teste e um ativador de canal de cálcio, preferivelmente um ativador de Icrac com uma população de células que expressam canais de cálcio, de preferência células que expressam Icrac contendo uma construção repórter compreendendo um gene repórter sob o controle de um promotor indutível por NFAT, e (b) determinar a atividade do composto de teste no canal ativado por liberação de cálcio, mediante avaliação da expressão do gene repórter nas ditas células.
BR0101294-0A 2000-04-03 2001-04-02 Métodos de triagem de um composto que modula a atividade do canal de cálcio, e para bloqueadores e para estimuladores de icrac, kit para uso em um método, célula sanguìnea ou célula derivada do sangue, linfócito ou célula derivada de linfócito, ou mastócito ou célula derivada de mastócito, e, população de células imunes de roedores BR0101294A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00400923A EP1143013A1 (en) 2000-04-03 2000-04-03 Methods and compositions for screening Icrac modulators

Publications (1)

Publication Number Publication Date
BR0101294A true BR0101294A (pt) 2001-11-06

Family

ID=8173631

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0101294-0A BR0101294A (pt) 2000-04-03 2001-04-02 Métodos de triagem de um composto que modula a atividade do canal de cálcio, e para bloqueadores e para estimuladores de icrac, kit para uso em um método, célula sanguìnea ou célula derivada do sangue, linfócito ou célula derivada de linfócito, ou mastócito ou célula derivada de mastócito, e, população de células imunes de roedores

Country Status (6)

Country Link
US (2) US6696267B2 (pt)
EP (1) EP1143013A1 (pt)
JP (1) JP2001314193A (pt)
BR (1) BR0101294A (pt)
CA (1) CA2342677A1 (pt)
MX (1) MXPA01003405A (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1511843T3 (da) * 2002-06-07 2006-07-24 Sophion Bioscience As Screeningsmetoder
US6929923B2 (en) * 2002-07-23 2005-08-16 Rigel Pharmaceuticals, Inc. Modulators of leukocyte activation, BIC compositions and methods of use
JP4383898B2 (ja) * 2003-02-28 2009-12-16 株式会社リコー 現像剤収容器、現像剤供給装置及び画像形成装置
US7645588B2 (en) 2003-03-04 2010-01-12 Calcimedica, Inc. Composition comprising a cell comprising a STIM1 protein and an agent that modulates intracellular calcium and methods of use
KR100776010B1 (ko) * 2005-02-26 2007-11-16 한국과학기술연구원 Ｔ-형 α1Ｈ 칼슘 채널의 고효율 억제제 검색 및 광범위 특성연구용 ＨＥＫ293 세포주
WO2007121186A2 (en) * 2006-04-10 2007-10-25 The Queen's Medical Center Crac modulators and use of same for drug discovery
WO2008148108A1 (en) 2007-05-24 2008-12-04 Calcimedica, Inc. Calcium channel proteins and uses thereof
CA2734500A1 (en) 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
HUE029570T2 (en) 2010-04-27 2017-03-28 Calcimedica Inc Intracellular calcium modifying compounds
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2563759B1 (en) 2010-04-27 2022-04-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
CN114712513B (zh) 2015-02-27 2026-02-10 钙医学公司 胰腺炎治疗
AU2016306301B2 (en) 2015-08-07 2021-02-11 Calcimedica, Inc. Use of CRAC channel inhibitors for the treatment of stroke and traumatic brain injury
TW201902875A (zh) 2017-03-15 2019-01-16 美商亞瑟尼克斯公司 聯芳基哌啶醯胺化合物及其使用方法
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
CN113557020A (zh) 2018-09-14 2021-10-26 瑞真药业公司 包含crac抑制剂和皮质类固醇的组合物及其使用方法
US12544371B2 (en) 2020-03-20 2026-02-10 Calcimedica, Inc. Methods and compositions for treating acute lung injury and acute respiratory distress syndrome
US12522589B2 (en) 2020-11-13 2026-01-13 Calcimedica, Inc. Synthesis of CRAC channel inhibitors
CN112442510A (zh) * 2020-11-29 2021-03-05 天津理工大学 一种耐糖高分泌型基因工程受体菌的构建方法
CN115369145B (zh) * 2022-01-19 2024-03-01 中国人民解放军军事科学院军事医学研究院 一种筛查乙酰胆碱酯酶抑制剂的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670113A (en) * 1991-12-20 1997-09-23 Sibia Neurosciences, Inc. Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same
US5741657A (en) * 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
US6004808A (en) * 1996-06-21 1999-12-21 Aurora Biosciences Corporation Promiscuous G-protein compositions and their use
AU4170597A (en) * 1996-08-30 1998-03-19 Regents Of The University Of California, The Method and compounds for controlling capacitative calcium ion entry into mammalian cells
HK1041009B (en) * 1998-12-30 2009-05-08 Beth Israel Deaconess Medical Center, Inc. Characterization of the soc/crac calcium channel protein family

Also Published As

Publication number Publication date
CA2342677A1 (en) 2001-10-03
MXPA01003405A (es) 2005-06-30
EP1143013A1 (en) 2001-10-10
JP2001314193A (ja) 2001-11-13
US20040121381A1 (en) 2004-06-24
US6696267B2 (en) 2004-02-24
US20020034728A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
Miyake et al. Identification of the hallmarks of necroptosis and ferroptosis by transmission electron microscopy
Kahan et al. Coordinate, biphasic activation of p44 mitogen-activated protein kinase and S6 kinase by growth factors in hamster fibroblasts. Evidence for thrombin-induced signals different from phosphoinositide turnover and adenylylcyclase inhibition.
Martı́n et al. 4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers
Lindgren et al. Activation of extracellular signal‐regulated kinases 1 and 2 by depolarization stimulates tyrosine hydroxylase phosphorylation and dopamine synthesis in rat brain
Schwarz et al. Non-melanoma skin cancer in mouse and man
Ohno et al. Activation of novel protein kinases C delta and C epsilon upon mitogenic stimulation of quiescent rat 3Y1 fibroblasts
Park et al. Induction of thioredoxin reductase as an adaptive response to acrolein in human umbilical vein endothelial cells
Warmka et al. Mitogen-activated protein kinase phosphatase-3 is a tumor promoter target in initiated cells that express oncogenic Ras
ATE316147T1 (de) Enzymsensor
ATE271130T1 (de) Veränderte proteinkinasen, die modifizierte nukleotidtriphosphat substrate verwenden können
Michard et al. Evaluation of cytotoxic properties of organometallic ferrocifens on melanocytes, primary and metastatic melanoma cell lines
ATE404867T1 (de) Verfahren und testbesteck zur beurteilung der oxidativen modifikation proteinhaltiger stoffe mittels messung ihrer antiradikalen aktivität
Becker et al. Ex vivo neurogenesis within enteric ganglia occurs in a PTEN dependent manner
McIlwrath et al. Overexpression of neurotrophin‐3 enhances the mechanical response properties of slowly adapting type 1 afferents and myelinated nociceptors
ATE50460T1 (de) Kontrollmittel fuer blutgasanalysatoren und haemoglobinbestimmung.
DE60137512D1 (de) Zusammensetzungen und verfahren zum nachweis und zur quantifizierung von cox-2-aktivität und 2-arachidonylglycerin-metaboliten
Lim et al. Metabolic signatures of renal cell carcinoma
Weng et al. O‐GlcNAcylation drives calcium signaling toward osteoblast differentiation: A bioinformatics‐oriented study
Kinoshita-Kikuta et al. Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers
Akiba et al. Secretory phospholipase A2 mediates cooperative prostaglandin generation by growth factor and cytokine independently of preceding cytosolic phospholipase A2 expression in rat gastric epithelial cells
DK0690991T3 (da) Ny antikoagulant-cofaktor-aktivitet
FR2745088B1 (fr) Procede pour tester une substance eventuellement active dans le domaine capillaire
He et al. Metabolomic analysis of dietary‐restriction‐induced attenuation of sarcopenia in prematurely aging DNA repair‐deficient mice
BR0211350A (pt) Ensaio homogêneo de ligação de biopolimero por meio de múltiplas medidas sob condições variadas
Kim et al. Conventional‐type protein kinase C contributes to phorbol ester‐induced inhibition of rat myometrial tension

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2012 DE 28/07/2009.